Contrasting BioRestorative Therapies (BRTX) and American Renal Associates (ARA)

BioRestorative Therapies (OTCMKTS:BRTX) and American Renal Associates (NYSE:ARA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for BioRestorative Therapies and American Renal Associates, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioRestorative Therapies 0 0 0 0 N/A
American Renal Associates 0 1 3 0 2.75

American Renal Associates has a consensus target price of $22.75, indicating a potential upside of 14.90%. Given American Renal Associates’ higher possible upside, analysts plainly believe American Renal Associates is more favorable than BioRestorative Therapies.

Institutional & Insider Ownership

92.7% of American Renal Associates shares are held by institutional investors. 43.2% of BioRestorative Therapies shares are held by insiders. Comparatively, 9.6% of American Renal Associates shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

BioRestorative Therapies has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, American Renal Associates has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Valuation and Earnings

This table compares BioRestorative Therapies and American Renal Associates’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioRestorative Therapies $80,000.00 127.13 -$9.44 million N/A N/A
American Renal Associates $745.11 million 0.86 $4.85 million $0.61 32.46

American Renal Associates has higher revenue and earnings than BioRestorative Therapies.


This table compares BioRestorative Therapies and American Renal Associates’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioRestorative Therapies -9,030.91% N/A -712.11%
American Renal Associates -1.11% 19.60% 2.39%


American Renal Associates beats BioRestorative Therapies on 9 of the 11 factors compared between the two stocks.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with's FREE daily email newsletter.

Leave a Reply